Results 141 to 150 of about 8,981 (169)

Systemic Inflammation, Intestine, and Paraoxonase-1

2014
Serum paraoxonase 1 (PON1) has been shown to act as an important guardian against cellular damage from oxidized lipids in low-density lipoprotein (LDL), plasma membrane, against toxic agents such as pesticide residues including organophosphates and against bacterial endotoxin.
Ladan, Vakili, Kaveh Daniel, Navab, Maryam, Shabihkhani, Nasim, Pourtabatabaei, Samra, Vazirian, Zarina, Barseghian, Seyedehsara, Seyedali, Greg, Hough   +7 more
openaire   +2 more sources

Variation in paraoxonase-1 activity and atherosclerosis

Current Opinion in Lipidology, 2009
Paraoxonase-1 (PON1) is an HDL-associated protein of 354 amino acids with a molecular mass of 43 000 Da. It is synthesized in the liver, and in serum it is almost exclusively associated with HDL. PON1 has been reported to be an important contributor to the antioxidant and anti-inflammatory activities of HDL.
Soran, Handrean, Younis, Nahla N., Charlton-Menys, Valentine, Durrington, Paul   +3 more
openaire   +3 more sources

Paraoxonase 1 (PON1) reduces macrophage inflammatory responses

Atherosclerosis, 2013
Paraoxonase 1 (PON1) was suggested to play an anti-inflammatory role. In the present study we questioned whether PON1 has a direct impact on macrophage inflammatory responses, and the possible functional implications of such effects.Ex-vivo studies were performed with bone marrow-derived macrophages (BMDM) harvested from C57BL/6 and human-PON1 ...
Saar, Aharoni, Michael, Aviram, Bianca, Fuhrman   +2 more
openaire   +2 more sources

Paraoxonase 1 Gene L55M Polymorphism and Paraoxonase 1 Activity in Obstructive Sleep Apnea Patients

2018
The antioxidant enzyme paraoxonase-1 (PON1) may limit oxidative stress in the development of cardiovascular diseases (CVD) and obstructive sleep apnea (OSA). The aim of the study was to determine PON1 gene L55M polymorphism in OSA-positive and OSA-negative subjects, along with paraoxonase activity of the enzyme (PON1-act).
A, Płóciniczak, A, Baszczuk, A, Ludziejewska, H, Winiarska, S, Michalak, G, Kasprzak, D, Formanowicz, S, Cofta, E, Wysocka   +8 more
openaire   +2 more sources

Paraoxonase-1 genetic polymorphisms in organophosphate metabolism

Toxicology, 2019
Organophosphates (OPs) are a class of chemicals commonly used in agriculture as pesticides, that can often lead to severe toxicity in humans. Paraoxonase-1 (PON1) belongs to a family of A-esterases and hydrolyses several OPs while also serving other biological roles.
Efthimios Dardiotis, Athina-Maria Aloizou, Vasileios Siokas, Zisis Tsouris, Dimitrios Rikos, Chrysa Marogianni, Michael Aschner, Leda Kovatsi, Dimitrios P. Bogdanos, Aristidis Tsatsakis   +9 more
openaire   +2 more sources

Paraoxonase 1 and Postprandial Lipemia

2008
Risk factors for coronary heart disease (CHD) include decreased insulin sensitivity and glucose intolerance, hypertension, increased body fat mass, unfavorable body fat distribution, the prothrombotic state and dyslipidemia. A clustering of these metabolic disturbances is also seen in Insulin Resistance and the metabolic syndrome.
A. Alipour, B. Coll, A.P. Rietveld, J. Marsillach, J. Camps, J. Joven, J.W.F. Elte, M. Castro Cabezas   +7 more
openaire   +1 more source

Paraoxonase 1 Mutations in a Turkish Population

Toxicology and Applied Pharmacology, 1999
Human serum paraoxonase 1 (PON1) catalyzes the hydrolysis of certain organophosphate pesticides and nerve gases and so may alter significantly an individual's susceptibility to the toxicity of these chemicals. Moreover, PON1 hydrolyzes lipid peroxides complexed to low density lipoproteins (LDL) and therefore it was suggested that PON1 may be one of the
A S, Aynacioglu, I, Cascorbi, P M, Mrozikiewicz, M, Nacak, E E, Tapanyigit, I, Roots   +5 more
openaire   +2 more sources

Antiepileptic drugs: Impacts on human serum paraoxonase‐1

Journal of Biochemical and Molecular Toxicology, 2016
AbstractSerum paraoxonase (PON1) is a key enzyme related to high‐density lipoprotein (HDL)‐cholesterol particle. It can prevent the oxidation of low‐density lipoprotein (LDL) and HDL. The present article focuses on the in vitro inhibition role of some antiepileptic drugs (AEDs) such as valproic acid, gabapentin, primidone, phenytoin, and levetiracetam ...
Demir, Yeliz, BEYDEMİR, ŞÜKRÜ
openaire   +3 more sources

Paraoxonase-1 promoter polymorphism C???107T and serum apolipoprotein AI interact to modulate serum paraoxonase-1 status

Pharmacogenetics and Genomics, 2005
The objective was to examine the hypothesis that modifications to paraoxonase-1 specific activity (SP, activity per unit mass peptide) could contribute to serum paraoxonase-1 status, a determinant of the clinical efficacy of the enzyme.Enzyme activities and concentrations were determined in a large population (n=912) of patients and controls.
Richard W, James, Barbara, Kalix, Silvana, Bioletto, Marie-Claude, Brulhart-Meynet   +3 more
openaire   +2 more sources

Paraoxonase-1 and Cardiovascular Disease

2008
The oxidation of low-density lipoprotein (LDL) in the artery wall is responsible for the initiation and progression of atherosclerosis. High-density lipoprotein (HDL) on the other hand is protective against atherosclerosis development and can attenuate the oxidation of LDL.
B. Mackness, M.I. Mackness
openaire   +1 more source